title: Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients.
abstract: Platelets are intimately involved in atherosclerosis, and hypertension is a known risk factor for coronary artery disease. The angiotensin-converting enzyme (ACE) inhibitors were demonstrated to reduce hypertension and attenuate atherosclerosis. Because increased platelet aggregation was shown in hypertensive patients, the effect of a new ACE inhibitor, fosinopril, on platelet aggregation was studied. Fosinopril therapy (10 mg/day for 4 weeks) in 18 male hypertensive patients showed > or = 31% reduction in ADP-induced platelet aggregation. In vitro studies showed that fosinopril had similar inhibitory effect on ADP-induced platelet aggregation. No inhibitory effect could be detected with collagen as the aggregating agent. Finally, inhibition of platelet aggregation by fosinopril was less effective in platelets derived from hypertensive patients as compared with platelets derived from normal subjects. We conclude that fosinopril possesses a significant inhibitory activity on ADP-induced platelet aggregation both in vitro and in vivo.
authors.affiliation: Rambam Medical Center, Rappaport Institute for Research in the Medical Sciences, The Bruce Rappaport Technion Faculty of Medicine, Haifa, Israel.
authors.forename: S
authors.initials: S
authors.lastname: Keidar
authors.forename: J
authors.initials: J
authors.lastname: Oiknine
authors.forename: A
authors.initials: A
authors.lastname: Leiba
authors.forename: C
authors.initials: C
authors.lastname: Shapira
authors.forename: M
authors.initials: M
authors.lastname: Leiba
authors.forename: M
authors.initials: M
authors.lastname: Aviram
mesh_terms: D000244:Adenosine Diphosphate / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D017328:Fosinopril / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D000244:Adenosine Diphosphate; D017328:Fosinopril